Search Results - "Legos, J J"

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

“…Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and…”
Get full text

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial by Grob, Jean Jacques, Prof, Amonkar, Mayur M, PhD, Karaszewska, Boguslawa, MD, Schachter, Jacob, Prof, Dummer, Reinhard, Prof, Mackiewicz, Andrzej, Prof, Stroyakovskiy, Daniil, MD, Drucis, Kamil, MD, Grange, Florent, MD, Chiarion-Sileni, Vanna, MD, Rutkowski, Piotr, Prof, Lichinitser, Mikhail, Prof, Levchenko, Evgeny, MD, Wolter, Pascal, MD, Hauschild, Axel, Prof, Long, Georgina V, MD, Nathan, Paul, MD, Ribas, Antoni, Prof, Flaherty, Keith, MD, Sun, Peng, PhD, Legos, Jeffrey J, PhD, McDowell, Diane Opatt, MD, Mookerjee, Bijoyesh, MD, Schadendorf, Dirk, Prof, Robert, Caroline, MD

“…Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Get full text

Caspase 3 Activation Is Essential for Neuroprotection in Preconditioning by McLaughlin, BethAnn, Hartnett, Karen A., Erhardt, Joseph A., Legos, Jeffrey J., White, Ray F., Barone, Frank C., Aizenman, Elias

“…Sublethal insults can induce tolerance to subsequent stressors in neurons. As cell death activators such as ROS generation and decreased ATP can initiate…”
Get full text

SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia by Barone, F C, Irving, E A, Ray, A M, Lee, J C, Kassis, S, Kumar, S, Badger, A M, White, R F, McVey, M J, Legos, J J, Erhardt, J A, Nelson, A H, Ohlstein, E H, Hunter, A J, Ward, K, Smith, B R, Adams, J L, Parsons, A A

“…The stress-activated mitogen-activated protein kinase (MAPK) p38 has been linked to the production of inflammatory cytokines/mediators/inflammation and…”
Get more information

Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia by Barone, F.C., Irving, E.A., Ray, A.M., Lee, J.C., Kassis, S., Kumar, S., Badger, A.M., Legos, J.J., Erhardt, J.A., Ohlstein, E.H., Hunter, A.J., Harrison, D.C., Philpott, K., Smith, B.R., Adams, J.L., Parsons, A.A.

“…Mitogen‐activated protein kinases (MAPKs) are involved in many cellular processes. The stress‐activated MAPK, p38, has been linked to inflammatory cytokine…”
Get full text

3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma by Robert, C, Karaszewska, B, Schachter, J, Rutkowski, P, Mackiewicz, A, Stroyakovskiy, D, Lichinitser, M, Dummer, R, Grange, F, Mortier, L, Chiarion-Sileni, V, Drucis, K, Krajsova, I, Hauschild, A, Mookerjee, B, Legos, J, Schadendorf, D

Get full text

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis by McQuade, Jennifer L, Daniel, Carrie R, Hess, Kenneth R, Mak, Carmen, Wang, Daniel Y, Rai, Rajat R, Park, John J, Haydu, Lauren E, Spencer, Christine, Wongchenko, Matthew, Lane, Stephen, Lee, Dung-Yang, Kaper, Mathilde, McKean, Meredith, Beckermann, Kathryn E, Rubinstein, Samuel M, Rooney, Isabelle, Musib, Luna, Budha, Nageshwar, Hsu, Jessie, Nowicki, Theodore S, Avila, Alexandre, Haas, Tomas, Puligandla, Maneka, Lee, Sandra, Fang, Shenying, Wargo, Jennifer A, Gershenwald, Jeffrey E, Lee, Jeffrey E, Hwu, Patrick, Chapman, Paul B, Sosman, Jeffrey A, Schadendorf, Dirk, Grob, Jean-Jacques, Flaherty, Keith T, Walker, Dana, Yan, Yibing, McKenna, Edward, Legos, Jeffrey J, Carlino, Matteo S, Ribas, Antoni, Kirkwood, John M, Long, Georgina V, Johnson, Douglas B, Menzies, Alexander M, Davies, Michael A

“…Obesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is…”
Get full text

Quantitative changes in interleukin proteins following focal stroke in the rat by Legos, Jeffrey J, Whitmore, Robert G, Erhardt, Joseph A, Parsons, Andrew A, Tuma, Ronald F, Barone, Frank C

“…The aim of the present study was to quantitate the temporal changes in protein concentration for interleukin (IL)-1α, IL-1β, IL-1ra, and IL-6 from 1 h to 15…”
Get full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial by Long, Georgina V, MD, Stroyakovskiy, Daniil, MD, Gogas, Helen, MD, Levchenko, Evgeny, MD, de Braud, Filippo, MD, Larkin, James, FRCP, Garbe, Claus, Prof, Jouary, Thomas, MD, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Lebbe, Celeste, Prof, Mandalà, Mario, MD, Millward, Michael, Prof, Arance, Ana, MD, Bondarenko, Igor, Prof, Haanen, John B A G, Prof, Hansson, Johan, Prof, Utikal, Jochen, Prof, Ferraresi, Virginia, MD, Kovalenko, Nadezhda, Prof, Mohr, Peter, MD, Probachai, Volodymr, MD, Schadendorf, Dirk, Prof, Nathan, Paul, MD, Robert, Caroline, MD, Ribas, Antoni, Prof, DeMarini, Douglas J, PhD, Irani, Jhangir G, MA, Swann, Suzanne, PhD, Legos, Jeffrey J, PhD, Jin, Fan, MD, Mookerjee, Bijoyesh, MD, Flaherty, Keith, MD

“…Summary Background Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free survival compared with…”
Get full text

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials by Schadendorf, Dirk, Long, Georgina V., Stroiakovski, Daniil, Karaszewska, Boguslawa, Hauschild, Axel, Levchenko, Evgeny, Chiarion-Sileni, Vanna, Schachter, Jacob, Garbe, Claus, Dutriaux, Caroline, Gogas, Helen, Mandalà, Mario, Haanen, John B.A.G., Lebbé, Céleste, Mackiewicz, Andrzej, Rutkowski, Piotr, Grob, Jean-Jacques, Nathan, Paul, Ribas, Antoni, Davies, Michael A., Zhang, Ying, Kaper, Mathilde, Mookerjee, Bijoyesh, Legos, Jeffrey J., Flaherty, Keith T., Robert, Caroline

“…Understanding predictors of long-term benefit with currently available melanoma therapies is the key for optimising individualised treatments. A prior pooled…”
Get full text

SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia by Legos, Jeffrey J., Erhardt, Joseph A., White, Raymond F., Lenhard, Stephen C., Chandra, Sudeep, Parsons, Andrew A., Tuma, Ronald F., Barone, Frank C.

“…The aim of the present study was to evaluate p38 MAPK activation following focal stroke and determine whether SB 239063, a novel second generation p38…”
Get full text

Stroke Genomics: Approaches to Identify, Validate, and Understand Ischemic Stroke Gene Expression by Read, Simon J., Parsons, Andrew A., Harrison, David C., Philpott, Karen, Kabnick, Karen, O'Brien, Shawn, Clark, Steven, Brawner, Mary, Bates, Stewart, Gloger, Israel, Legos, Jeffrey J., Barone, Frank C.

“…Sequencing of the human genome is nearing completion and biologists, molecular biologists, and bioinformatics specialists have teamed up to develop global…”
Get full text

Pharmacological interventions for stroke: failures and future by Legos, Jeffrey J, Tuma, Ronald F, Barone, Frank C

“…Given the few options currently available for patients following ischaemic stroke, the recent disappointing failures of several large-scale Phase III clinical…”
Get more information

Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs by Hay, Douglas W P, Giardina, Giuseppe A M, Griswold, Don E, Underwood, David C, Kotzer, Charles J, Bush, Brian, Potts, William, Sandhu, Punam, Lundberg, Dave, Foley, James J, Schmidt, Dulcie B, Martin, Lenox D, Kilian, David, Legos, Jeffrey J, Barone, Frank C, Luttmann, Mark A, Grugni, Mario, Raveglia, Luca F, Sarau, Henry M

“…In this report the in vitro and in vivo pharmacological and pharmacokinetic profile of…”
Get more information

PP 65 Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant? by Ascierto, P.A, Gentilcore, G, Madonna, G, Assunta, E, Pirozzi, G, De Maio, E, Curvietto, M, Palmieri, G, Mozzillo, N, Legos, J

Get full text

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency by HONG, David S, VENCE, Luis, LIZEE, Gregory, HWU, Patrick, FALCHOOK, Gerald, RADVANYI, Laszlo G, CHENGWEN LIU, GOODMAN, Vicki, LEGOS, Jeffery J, BLACKMAN, Sam, SCARMADIO, Antonio, KURZROCK, Razelle

“…An intact immune system likely contributes to the outcome of treatment and may be important for clearance of drug-resistant tumor cells and for prevention of…”
Get full text

Expression of PEP-19 inhibits apoptosis in PC12 cells by Erhardt, Joseph A, Legos, Jeffrey J, Johanson, Roy A, Slemmon, J Randall, Wang, Xinkang

“…PEP-19 is a calmodulin-regulatory protein found specifically within neurons, though cellular functions of this protein have not been determined. In an effort…”
Get full text

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist by Sarau, H M, Griswold, D E, Bush, B, Potts, W, Sandhu, P, Lundberg, D, Foley, J J, Schmidt, D B, Webb, E F, Martin, L D, Legos, J J, Whitmore, R G, Barone, F C, Medhurst, A D, Luttmann, M A, Giardina, G A, Hay, D W

“…The pharmacological and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-car boxami de], a human NK-3 receptor…”
Get more information

Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice by Barone, Frank C, Barton, Matthew E, White, Ray F, Legos, Jeffrey J, Kikkawa, Hideo, Shimamura, Midori, Kuratani, Kazuyoshi, Kinoshita, Mine

“…Phosphodiesterase type 4 (PDE4) has been previously shown to regulate colonic contractile activity in vitro. In this study, the effects of PDE4 inhibition were…”
Get more information